OXNARD, CALIFORNIA – CURE Pharmaceutical will be collaborating with Canopy Growth Corp. to produce low-dose cannabidiol (CBD) oral thin film (OTF) to help administer CBD in the right dosages. This collaboration will leverage CURE’s patented technology, CUREfilm and will also allow the two companies to distribute CBD globally.
“This collaboration builds on our licensing agreement with canopy and accelerates product commercialization,” according to Rob Davidson, the Chief Executive Officer of CURE Pharmaceutical. “We will leverage our recent patented development in cannabis-based drug delivery, to formulate an oral thin film product for optimal efficacy and dosing frequency.”
More About Cure
CURE Pharmaceutical is a registered company under the U.S. Drug Enforcement Agency (DEA). It makes use of its patented CUREfilm technology in developing and manufacturing cannabis-derived and synthetic CBD-based products. It is also a known company that is federally-compliant on the regulations of its industry even during collaborations with other CBD growers and manufacturers.